Francesco Sparano

Patient-reported outcomes researcher. Health Outcomes Research Unit @FGIMEMA

[JCO Oncology Practice @JCOOP_ASCO]

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

Read the full article. https://t.co/dhudePkXvR
#healthequity

[Francesco Sparano @_Fra_Spa]

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma | JCO Oncology Practice https://t.co/VVCj0AOk5i

[Ajay Major, MD, MBA @majorajay]

Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from #ASH24. 🧵 #ASHEducation #ASHKudos cc @ASH_hematology

[JCO Global Oncology @JCOGO_ASCO]

Health-Related Quality of Life and Financial Burden in Ethiopian Patients with Chronic Myeloid #Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study. https://t.co/vArMTbBu6w @FGIMEMA #QoL

[Raj Chakraborty @rajshekharucms]

Led by med student Darshi Shah and in collaboration with Fabio Efficace @FGIMEMA, we present the most comprehensive landscape of PROs in #MultipleMyeloma RCTs at #EHA24!
▪️ PRO domain most sensitive to change: GHS/QoL
▪️ Most common experimental arms associated with improved PROs: Anti-CD38mAb > PI > IMiD
▪️ Direction of PRO improvement concordant with OS in 71%, but with PFS in just 58% of RCTs!
▪️ Extremely heterogeneous methodology with 22 different MIDs used in 35 RCTs (highlights why its challenging to use in clinical practice or for regulatory decisions)

Stay tuned for the paper!
#mmsm

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

On behalf of @ic_MDS, & under leadership of Dr Fabio Efficace, we have published a position statement emphasizing importance of measuring Patient reported outcomes #PROs in #MDSsm clinical trials with detailed practical considerations @Hemasphere_EHA https://t.co/8m5xL19dTy

[Francesco Sparano @_Fra_Spa]

We also observed that not receiving a salary and having comorbidities are associated with an increased risk of experiencing FT. Interventions to manage return to work and assist with employment are critical to minimise the risk of FT in the most vulnerable long-term survivors

[Francesco Sparano @_Fra_Spa]

Happy to share a new paper just published in @BMJ_SPCare
Financial toxicity and health-related quality of life in long-term survivors of acute promyelocytic leukaemia
https://t.co/fVv2I56B0g

[Francesco Sparano @_Fra_Spa]

We found that even many years after being diagnosed, one-fifth of long-term survivors of APL treated in a universal healthcare system experience #financialtoxicity, and their HRQoL is generally impaired compared with long-term survivors without FT

[Fondazione GIMEMA @FGIMEMA]

📺 Oggi alle 11:40 e 21:40 su Rainews24 andrà in onda l'intervista realizzata dal programma Basta la Salute, in cui il presidente della fondazione GIMEMA, Marco Vignetti, parlerà del tema della tossicità finanziaria.
Anche in diretta streaming su https://t.co/fxu46SrVYb.

[Fondazione GIMEMA @FGIMEMA]

#risutatiGIMEMA
Uno studio appena pubblicato sulla rivista JCO - Oncology practice, coordinato dai ricercatori GIMEMA, indica che il problema della “tossicità finanziaria” riguarda anche i malati emato-oncologici che vivono in Italia.
CLICCA SULLA FOTO ⤵️
https://t.co/yni9OkPsLt

[Jens Lehmann @JLehmann_IBK]

We recently published the Danish data set for the EORTC QLU-C10D 🙂
Our data can be used to conduct health economic analysis based on QLQ-C30 data.

Also, the data give interesting info on how important different domains if QOL are rated by the general population📉⬇️

[Francesco Sparano @_Fra_Spa]

Happy to share a new paper published today in @JCOOP_ASCO
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System | JCO Oncology Practice https://t.co/p7AZM27G5Z

[Ajay Major, MD, MBA @majorajay]

Happy #ASH23! Announcing this year's #MajorPROsASH, the top 20 patient-reported outcomes & quality of life abstracts at the 2023 @ASH_hematology Annual Meeting. We even got our own PRO oral session this year! Follow along in this thread. 🧵#MajorPROs

[Elizabeth Eisenhauer @EAEisenhauer]

Recent publication from Brundage et al and our team - turns out when cancer pts are educated as to what PFS means, “treatments that impact negatively on quality of life were not preferred by most patients for PFS gains alone”

https://t.co/8euQenQKQl

@csoncol

[EORTC Quality of Life Group (QLG) @EORTC_QLG]

📅Upcoming poster presentation at #EHA2023 by Prof. Fabio Efficace on "Long-term comorbidity and health problems in acute myeloid leukemia (AML) survivors: An international AML survivorship study"

Read more in the abstract 👇
https://t.co/PPviFgRaaj

@FGIMEMA #QualityofLife

[Massimo Di Maio @MassimoDiMaio75]

Proud of this publication, the first original article in the new @bmj_company Oncology journal.

@LauraMarandino @EleonoraGhisoni @marialuciareale @paslombardi @JamesAimar @valedoc87 @chiaramallow @fabioturco92 @R_DiLiello @fperrone62

Tweetorial (1/6)

https://t.co/e8dyg3og7O

[Materia @materia_ciencia]

Las terapias celulares han salvado a pacientes con tumores de la sangre que deberían haberlos matado hace años.

Este tratamiento basado en un autotrasplante de células inmunes parecía ciencia ficción hace 10 años, pero hoy se usa en la clínica

https://t.co/y13uOZibL5

[Eric Topol @EricTopol]

Missing the🎯
For 627 #AI clinical trials, a systematic review (1997-2022) shows that only 24% used patient-reported outcome measures
https://t.co/CIbzzayqOs @LancetDigitalH
@Denniston_Ophth @drmelcalvert and colleagues

[Altreconomia @altreconomia]

Esiste un doppio legame tra la crisi climatica e la fragilità degli Stati a rischio: gli effetti dei cambiamenti climatici peggiorano i conflitti e a loro volta sono amplificati dalle crisi. Eppure sono proprio i Paesi a rischio a ricevere minori risorse https://t.co/WRM7vadjqF